BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL501 for Acute Treatment of Agitation

Dec 27, 2018

BioXcel Therapeutics Doses First Subjects in Pharmacokinetic (Bioavailability) and Safety Study of BXCL501 for the Acute Treatment of Agitation

Dec 19, 2018

BioXcel Therapeutics Announces FDA Acceptance of IND for Lead Neuroscience Candidate, BXCL501 for the Acute Treatment of Agitation

Dec 12, 2018

BioXcel Therapeutics to Present at BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference

Dec 3, 2018

BioXcel Therapeutics Reports Positive Results from Study in Agitated Schizophrenia Patients Supporting BXCL501 Clinical Development

Nov 14, 2018

BioXcel Therapeutics Reports Third Quarter 2018 Quarterly Results and Provides Business Update

Nov 9, 2018

BioXcel Therapeutics Announces FDA Acceptance of IND for Lead Immuno-oncology Candidate, BXCL701, in Treatment Emergent Neuroendocrine Prostate Cancer

Nov 5, 2018

BioXcel Therapeutics to Host Third Quarter 2018 Financial Results and Business Update Conference Call

Nov 2, 2018

BioXcel Therapeutics Announces Presentation on Functional Immunological Memory Formation Across Diverse Tumor Types at the SITC 2018 Annual Meeting

Oct 31, 2018

BioXcel Therapeutics Provides Update on the Clinical Advancement of BXCL501 for the Acute Treatment of Agitation

Oct 30, 2018